COMMUNIQUÉS West-GlobeNewswire

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
13/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
13/01/2026
Exclusive U.S. Distribution Partnership with Enlight Medical Ltd. Enables Kaneka Medical America LLC to Bring Novel Neurovascular Guidewire Technology to the U.S. Market NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- [...]
Southern Pain and Spine Specialists Announces Dr. Ammar Alamarie, MD Named Castle Connolly Top Doctor for Pain Management in 2025 for Second Consecutive Year
13/01/2026
Dr. Ammar Alamarie’s second consecutive Castle Connolly Top Doctor honor for Pain Management, recognizing his clinical excellence, leadership, and compassionate, innovative patient-centered care nationwide. Matthews, NC [...]
Metabo Drops Examined: Is It Legit for Weight Loss? Safety Checks and Consumer Analysis 2026
13/01/2026
New York, NY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Consumer interest in supplement legitimacy continues to rise as transparency becomes a deciding factor in purchasing decisions. Searches that include phrases such as “Is [...]
SPINEWAY : 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%)
13/01/2026
Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros 2025 2024 Change as a % H1 revenue 5,573 6,535 -15% H2 revenue 6,857 5, [...]
SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%)
13/01/2026
Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros 2025 2024 Variation en % CA 1 er semestre 5 573 6 535 - 15% CA [...]
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
13/01/2026
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: [...]
La FDA américaine accorde la désignation « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie intensive
13/01/2026
La désignation « Breakthrough Therapy » a été accordée pour la thérapie expérimentale IPN60340 en association avec le vénétoclax et l’azacitidine dans la leucémie myéloïde aiguë de première ligne chez les patients [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
13/01/2026
Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2025
13/01/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
13/01/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2026 – GENFIT (Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
13/01/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Synfini Assessed ‘Awardable’ for DARPA ERIS Marketplace
13/01/2026
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Synfini , a leading provider of the industry’s most innovative Agile AI Foundry for drug discovery, today announced that it has achieved “Awardable” status through [...]
Evermore Extends Industry-Leading Retail Partnership with the Addition of United Supermarkets
13/01/2026
BENTONVILLE, Ark., Jan. 13, 2026 (GLOBE NEWSWIRE) -- evermore, the personalized health benefits platform transforming how people access the resources they need to live healthier lives, today announced a new partnership [...]
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
13/01/2026
New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseases HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
13/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 13 January 2026 at 16.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
13/01/2026
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying [...]
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
13/01/2026
WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and [...]
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
13/01/2026
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “ [...]

Pages